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In particular, neuropathic pain is a major form of chronic pain. This type of pain results
from dysfunction or lesions in the central and peripheral nervous system. Capsaicin
has been traditionally utilized as a medicine to remedy pain. However, the effectiveness
and safety of this practice is still elusive. Therefore, this systematic review aimed to
investigate the effect of topical capsaicin as a pain-relieving agent that is frequently used
in pain management. In brief, all the double-blinded, randomized placebo- or vehicle-
controlled trials that were published in English addressing postherpetic neuralgia were
included. Meta-analysis was performed using Revman©R version 5.3. Upon application
of the inclusion and exclusion criteria, only six trials fulfilled all the criteria and were
included in the review for qualitative analysis. The difference in mean percentage change
in numeric pain rating scale score ranges from −31 to −4.3. This demonstrated high
efficacy of topical capsaicin application and implies that capsaicin could result in pain
reduction. Furthermore, meta-analysis was performed on five of the included studies.
All the results of studies are in favor of the treatment using capsaicin. The incidence of
side effects from using topical capsaicin is consistently higher in all included studies,
but the significance of safety data cannot be quantified due to a lack of p-values in
the original studies. Nevertheless, topical capsaicin is a promising treatment option
for specific patient groups or certain neuropathic pain conditions such as postherpetic
neuralgia.
Keywords: pain, postherpetic neuralgia, topical agent, capsaicin, Capsicum
INTRODUCTION
Pain is described as an unpleasant sensory and emotional experience associated with actual or
potential tissue damage (Bode and Dong, 2011; Desai et al., 2012; Simon, 2012). There are two
common types of pain, acute pain and chronic pain. Basically, acute pain is crucial in alerting an
individual to withdraw from a harmful situation while chronic pain could be constitute of serious,
separate disease entity (Desai et al., 2012). For more detailed information, chronic pain is highly
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prevalent, affecting over 1.5 billion people worldwide (National
Center for Health Statistics, 2007; Medeiros and Winsler, 2014).
It is noteworthy that chronic pain affects more people than other
chronic conditions such as diabetes, heart disease and cancer
(Simon, 2012). The annual costs of chronic pain in the United
States (including the total incremental cost of health care and
cost of lost productive time) are estimated to be at least USD 560
billion (Medeiros and Winsler, 2014). As suggested by studies,
chronic pain has a huge detrimental effect on the quality of life
of patients (National Center for Health Statistics, 2007; Medeiros
and Winsler, 2014). Undeniably, chronic pain is a significant
healthcare issue, as it poses an enormous burden on patients,
society and the healthcare system (Medeiros and Winsler, 2014).
In particular, neuropathic pain is a major form of chronic
pain. Neuropathic pain results from dysfunction or lesions in
the central and peripheral nervous system (Bridges et al., 2001;
Campbell and Meyer, 2006; Treede et al., 2008; Nickel et al.,
2012). Neuropathic pain conditions include HIV neuropathy
(neurological complication of HIV) and postherpetic neuroglia
(Derry et al., 2013). Postherpetic neuralgia (PHN) is a debilitating
complication of herpes zoster ophthalmicus (HZO), commonly
known as shingles, especially in elderly patients (Bucci et al.,
1988). Besides, it is estimated that 10–15% of patients who have
shingles will experience PHN (FDA, 2009). In particular, this
disease is characterized by a distinctive syndrome—a painful
skin rash mainly caused by reactivation of varicella zoster virus
(VZV), especially if there is immunity to VZV drops due to
aging or immunosuppression (Johnson and Whitton, 2004).
Unfortunately, current treatment modalities such as tricyclic
antidepressants and anticonvulsants are largely unsuccessful (due
to adverse effects, poor tolerability and slow onset of action)
(Bucci et al., 1988; Backonja et al., 2008). Unlike nociceptive
pain, neuropathic pain such as PHN cannot be relieved by
conventional analgesics such as paracetamol (Bridges et al., 2001).
To make the scenario even worse, the prolonged and unresolved
excruciating pain resulting from PHN often leads to depression,
and in extreme cases suicide (Bucci et al., 1988).
Over the last three millennia, human civilization has relied
on natural products derived from plants, animals and microbial
origins to alleviate and cure sickness (Tan et al., 2015a,b; Tang
et al., 2016; Yuan et al., 2016). From as far back as 60,000 years
ago, in the Middle Paleolithic Age, there is evidence that humans
were using plants as medicines (Fabricant and Farnsworth,
2001). The use of plants in traditional medical systems such
as Ayurveda, Unani, Kampo and traditional Chinese medicine
have flourished for 1000s of years (Fabricant and Farnsworth,
2001; Tan et al., 2016a,b). Although medical science views such
systems as lacking credibility and scientific logic, it is notable
that a lot of plant-originated drugs in current clinical medicine
were derived from traditional medicine and serve as platforms
for modern drug development. Most importantly, those products
have become resources for developing new lead compounds and
scaffolds (Fabricant and Farnsworth, 2001; Chan et al., 2016; Tan
et al., 2016c). Given that over one-third of the world’s population,
mainly in rural areas, lacks regular access to affordable modern
medicines, the majority of people from countries in Africa, Asia
and Latin America largely rely on traditional medicine, which is
widely available to help meet some of their primary health care
needs (Zhang, 2004; Verma and Singh, 2008).
Plants are reported to have been traditionally used as
analgesics or resources for compounds with pain-relieving effects
(Hamilton and Baskett, 2000; Tan et al., 2015a; Chan et al.,
2016). For instance, opiate receptor agonists from poppy seeds
and cyclooxygenase inhibitors from willow bark are widely
used to alleviate pain in ancient medicine (Brownstein, 1993;
Thun, 2000). Chili is also one of the sources for analgesic
medications derived from plants. The ‘chili’ or ‘chili pepper’
plant, which is categorized under the genus Capsicum, belongs
to a dicotyledonous group of flowering plants. The taxonomic
position of Capsicum can be represented as follows: Kingdom –
Plantae; Division – Magnoliophyta; Class – Magnoliopsida;
Order – Solanales; Family – Solanaceae; Genus – Capsicum;
Species – chinense/annuum/pubescens/etc. (Basu and Krishna,
2003).
Since ancient times, chili has been recognized for its broad
range of therapeutic properties, and has been used for centuries
to remedy pain. Several external and internal applications have
been reported in various streams of traditional medicine (Khan
et al., 2014; Maji and Banerji, 2016). Externally, it is used
to treat different types of pain including rheumatism (joint
pain), lumbago (lower back pain) and neuralgia (pain spread
through nerves) (Khare, 2004). It can also be used as a local
stimulant, counter-irritant, and rubefacient (Iwu, 1993; Panda,
1999). Internally, chili is used to treat dyspepsia, loss of appetite,
flatulence, atherosclerosis, stroke, heart disease, and muscle
tension (Panda, 1999; Khare, 2004). In Unani medicine, chili is
utilized to prevent colds, sinus infections and sore throats, and
to improve digestion and blood circulation (Khare, 2004). In folk
medicine, it is suggested to treat cancer, asthma, bronchitis and
cough. In addition, its regular consumption is also believed to
be beneficial for anorexia, hemorrhoids, liver congestion, and
varicose veins (Duke and DuCellier, 1993).
The broad traditional usage of chili has prompted the
identification of capsaicin as the main active component of
a variety of chili peppers such as habaneros and jalapeños.
Capsaicin is responsible for causing the ‘hot’ and sharp pungent
sensation (Bode and Dong, 2011). Those properties have been
suggested to act through counter-irritation, which results in
analgesic effects. Modern usage of capsaicin focuses on the
treatment of various types of pain (Cortright et al., 2007). In
fact, capsaicin has been studied clinically as a topical treatment
for the pain of rheumatoid and osteoarthritis (Persson et al.,
2016), psoriasis, diabetic neuropathy, and postherpetic neuralgia
(Srinivasan, 2015). However, the efficacy of capsaicin in the
treatment of these chronic pain disorders is still elusive.
In order to have a better understanding of the various action
of capsaicin, studies have focused on the mechanism of capsaicin
in pain induction (Cortright et al., 2007). It is known as a selective
TRPV1 receptors ligand. The burning sensation is triggered
upon the binding of capsaicin to the receptors. It is believed
that the analgesic effect of capsaicin is due to its ability to
cause reversible desensitization or defunctionalization, where
the TRPV1-containing sensory axons become unresponsive to
stimuli during the long-lasting refractory period (Bode and Dong,
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FIGURE 1 | The potential of capsaicin as first-line treatment in PHN.
2011; Derry et al., 2013). As a result, after repeated exposure to
capsaicin, pain transmission is prevented and the pain response
is reduced (Derry et al., 2013). As such, it is different from other
naturally occurring irritant components. This feature of capsaicin
has been exploited for therapeutic use for many years. Other than
that, its ability to cause reversible nerve-fiber degeneration also
contributes to the analgesic effect (Bode and Dong, 2011; Derry
et al., 2013).
Conventionally, topical capsaicin has been used in pain
management in numerous neuropathic pain conditions. FDA
(2009), the Qutenza patch, a pure, synthetic capsaicin-containing
prescription drug, was approved by the Food and Drug
Administration (FDA) for long-term pain relief for PHN patients.
In spite of that, its safety has been much debated. This is
mainly because capsaicin is associated with some severe side
effects such as capsaicin-induced dermal pain and contact
dermatitis (human hand) (Bode and Dong, 2011). Topical
capsaicin products such as Qutenza may cause a significant
rise in blood pressure, necessitating the need for blood-pressure
monitoring by health care professionals (FDA, 2009). Emerging
evidence has also suggested that long-term application of topical
capsaicin may be harmful. As mentioned previously, capsaicin
exerts its therapeutic action by the desensitization process.
Therefore, prolonged use of topical capsaicin may lead to
persistent desensitization. Furthermore, multiple epidemiology
studies have suggested that capsaicin may have carcinogenic
properties. Its effectiveness has also not been fully established
(Bode and Dong, 2011). Additionally, the effectiveness of topical
capsaicin varies among patients with different conditions. It also
seems to have inconsistent effectiveness across neuropathic pain
conditions.
At the same time, there is a lack of comprehensive reviews
on the effectiveness of capsaicin on PHN. Furthermore, earlier
reviews have not included recent evidence (from research
conducted using more rigorous and stringent standards). There
is a need to conduct a literature review that includes the recent
studies. By doing so, we will be able to investigate the effectiveness
and safety of topical capsaicin using recent evidence.
The PICO framework is utilized to develop the main question
(Gray, 2003). By referring to the relevant review articles and
papers, the research question is further refined. The research
question is: ‘Is topical capsaicin efficacious and safe (compared to
a placebo) to be used as a first-line treatment in the management
of chronic neuropathic pain (particularly PHN) in adult and
elderly patients?’ By critically appraising the included studies, we
will investigate the efficacy and safety of topical capsaicin in pain
management. Topical capsaicin is usually prescribed as a third-
line treatment or adjunctive treatment (Argoff, 2011). Based on
the findings, we will evaluate its risk-benefit ratio and explore the
feasibility of using topical capsaicin as a first-line treatment in
PHN (Figure 1). It could potentially be used as a first-line option
if it shows adequate efficacy and safety.
METHOD
A systematic literature search was performed using databases
including PubMed, Medline, Embase, Science Direct and Google
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Scholar. Cochrane Library and Wiley Library were also used to
retrieve related papers.
Data Sources
A search string was developed using the keywords in the
topic, their synonyms and different registered brand names of
capsaicin. The search string used was (topical capsaicin OR
topical capsicin∗ OR topical capsicum OR topical analgesic∗
OR Capsagel OR Salonpas-Hot OR Zostrix OR Trixaicin OR
Qutenza) AND (continu∗ OR last∗ OR prolonged OR chronic OR
persist∗) AND (postherpetic neuralgia OR PHN) AND (pain OR
ache). Search techniques such as Boolean operators, truncation,
citation tracking, and chaining were also applied to retrieve
relevant resources.
Study Selection
Eligible studies were selected based on a set of inclusion criteria.
Based on the inclusion criteria, studies were included only
if they were double-blinded, randomized placebo- or vehicle-
controlled trials that were published in English. The type of
chronic pain considered was neuropathic pain (limited to only
postherpetic neuralgia) and the considered dosage forms were
creams and patches (topical). Both high- and low-concentration
capsaicin were considered in the review. The minimum duration
of the included studies was 6 weeks while the minimum age of
participants was 18 (adults and elderly). Only studies that used a
placebo or vehicle as the control arm were considered.
A PRISMA diagram was used to depict the flow of information
through different phases for the systematic review (Liberati et al.,
2009).
Analysis Strategy
Finally, the methodological quality of the included studies was
assessed using the Jadad scale. The studies were allocated a score
(from zero to five) that indicated the quality of the study (based
on randomization, blinding and withdrawal or dropout in the
study).
The risk of bias of the studies was assessed using Cochrane
Collaboration’s tool, where seven domains of bias are addressed.
Each domain was assigned high, low or unclear risk. The
numerical data for primary and secondary outcomes was
extracted and tabulated, and the missing data was calculated
where possible. For example, the confidence interval was
calculated using standard error and standard deviation. The
intention to treat (ITT) principle was applied in the analysis of
data.
Meta-analysis was performed on five studies that had sufficient
data. A forest plot was constructed to graphically summarize the
results of the included studies for the primary outcome (Schriger
et al., 2010). The heterogeneity of the studies was also assessed.
Using RevMan, the weighted average of studies was calculated.
Additionally, a risk of bias graph and summary was constructed.
Outcomes
The primary outcome is a clinically significant reduction in pain
and the response to treatment. This is indicated by:
(i) Difference in mean percentage change in 11-point
numeric pain rating scale (NPRS) or visual analog pain
scale (VAS) from baseline to weeks 2–12 or baseline to
weeks 2–6;
(ii) Reduction in NPRS score of more than 30 and/or 50% at
the end of the trial;
(iii) Mean reduction in seven-point patient global
impression of change (PGIC).
A secondary outcome is any side effect or adverse effect,
including musculoskeletal disorder, hyperalgesia, fatigue,
vomiting, transient hypertension, stinging, and erythema at
application site.
RESULTS
Initially, a total of 109 records were identified using the search
string (105 were found from Pubmed and Cochrane databases).
There were 41 results remaining after duplicate results were
removed. After screening the results using the inclusion and
exclusion criteria described earlier, 34 results were excluded. The
eliminated results include six reviews, two integrated studies, two
short articles, one case series, one letter to an editor, four studies
published only as abstract, one study that directly compared the
efficacy of two agents, one preliminary study, two open label
studies and a number of randomized controlled trials that were
out of the research scope. Watson et al. (1993), which consists of
both the double-blind phase and the long-term open-label phase,
was included. However, only the results from the double-blind
phase were analyzed. By further analyzing the full text of the
seven remaining papers, only six fulfilled all the inclusion and
exclusion criteria and were included in the review for qualitative
analysis. Backonja et al. (2010), whose study lasted only 4 weeks,
was excluded. All studies were included in quantitative analysis
except Bernstein et al. (1989), due to the limited quantitative data.
Due to the limited number of recent studies, publications
dated from 1989 to 2010 were included. However, most of the
included studies are recent studies. The process of the literature
search is depicted in the PRISMA flow chart attached (Figure 2).
Characteristics of Participants
A total number of six studies (1449 patients) that fulfilled the
inclusion criteria and exclusion criteria were included. Only adult
patients aged 18 and above were considered. Elderly patients
aged over 75 were also included in some studies (e.g., Bernstein
et al., 1989). The gender ratio and baseline characteristics
were unbalanced in some studies. The participants experienced
chronic neuropathic pain for at least 3 months. The number of
patients in the treatment arm ranged from 16 to 222 (Table 1).
Qualitative Analysis
Based on Table 2, all the results of studies favor the treatment
(capsaicin). The difference in mean percentage change in NPRS
score ranges from −31 to −4.3. Topical capsaicin demonstrated
high efficacies in Bernstein et al. (1989) (highest mean reduction
in NPRS score of −31), and lowest efficacy in Irving et al. (2011)
Frontiers in Pharmacology | www.frontiersin.org 4 January 2017 | Volume 7 | Article 538
fphar-07-00538 January 7, 2017 Time: 14:56 # 5
Yong et al. Capsaicin: Postherpetic Neuralgia Treatment
FIGURE 2 | PRISMA flow chart.
TABLE 1 | Characteristics of studies.
Studies Type of studies Mean
age
Type of
neuropathy
conditions
Male/female Participants (N) Capsaicin
concentration in
treatment arm
Treatment
duration
Jadad
score
Backonja et al.,
2008
Double-blind RCT 71 PHN 190/212 404 (T = 206, C = 196) 8% (high) 12 weeks 4
Webster et al.,
2010a
Double-blind RCT 71 PHN 150/149 299 (T = 222, C = 77) 8% (high) 12 weeks 4
Webster et al.,
2010b
Double-blind RCT 70 PHN 72/83 155 (T = 102, C = 53) 8% (high) 12 weeks 4
Irving et al.,
2011
Double-blind RCT 70 PHN 190/226 416 (T = 212, C = 204) 8% (high) 12 weeks 4
Watson et al.,
1993
Double-blind RCT 71 PHN 53/90 143 (T = 74, C = 69) 0.075% (low) 6 weeks 4
Bernstein et al.,
1989
Double-blind RCT 72 PHN 12/20 32 (T = 16, C = 16) 0.075% (low) 6 weeks 4
RCT, randomized controlled trials; PHN, postherpetic neuralgia; T, treatment; C, control.
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(mean reduction in NPRS score of −4.3). The results imply that
capsaicin could result in pain reduction.
There is discrepancy in the key findings (see Table 3). While
most studies report that capsaicin is efficacious and/or safe,
Webster et al. (2010b) suggest otherwise. However, it should be
noted that the results of Webster et al. (2010b) are statistically
insignificant as the p-value is greater than 0.05. As shown in
Table 2, a risk ratio of more than one is calculated for almost
all the studies except Webster et al. (2010a). The number of
participants who have a reduction in NPRS score of more than
30% was not measured in either Bernstein et al. (1989) or Watson
et al. (1993). Webster et al. (2010b) has a p-value of greater than
0.05, indicating that the results may be insignificant. The number
of participants who have a reduction in NPRS score of more than
50% was only measured in Webster et al. (2010a,b) and Irving
et al. (2011). Similarly, the results of Webster et al. (2010b) may
be insignificant (p-value > 0.05).
In terms of PGIC (Table 4), the number of patients who
reported improvements (slightly, much or very much) in pain
reduction is higher in the treatment group in all the studies. This
suggests that capsaicin may be effective in pain reduction (as
perceived by the patients). All results are significant (p < 0.05).
The p-value for Webster et al. (2010a) is unavailable, so the
significance of its results could not be determined. In terms of
the secondary end points (Table 4), the number and percentage
of patients who experience side effects is higher in the treatment
group. The trend is consistent in all studies. This suggests that
the use of topical capsaicin may be unsafe due to its side effects (as
suggested by earlier studies) (Bode and Dong, 2011). The p-values
(and hence significance) of the safety data from all seven studies
are unknown.
Based on Figure 3, most of the risks of bias of the included
studies are acceptably low. All studies have low risks of
performance bias, attrition bias and detection bias. However, all
studies have an unclear risk of selection bias (random sequence
generation) and reporting bias. Most studies (83.33%) have
unclear risks of selection bias (allocation concealment) and
reporting bias. Only 16.67% of the studies have low risk of these
two biases. In terms of size of study, only 33.33% of the studies
have a low risk of bias. The remaining studies have unclear risk
(50%) or high risk (16.67%). All studies have an unclear risk of
other bias.
In Figure 4, Backonja et al. (2008) has the lowest risk of bias
(low risk in five items and unclear risk of bias in three items). On
the other hand, Bernstein et al. (1989) (low risk in three items,
unclear risk in four items, high risk in one item) has the highest
risk of bias. The rest of the studies have acceptably low risks
of bias. Based on these analyses, most studies have moderately
high validity. Overall, the methodological quality of the included
studies is satisfactory, as all studies have a score of 4 out of 5. The
heterogeneity is found to be 0%, indicating that it is likely to be
insignificant (Higgins and Green, 2011).
Quantitative Analysis
Meta-analysis was performed on five of the included studies.
As seen in the forest plot, topical capsaicin displays varying
degree of efficacies in each study. All the results of studies
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TABLE 3 | Summary of outcomes and key findings.
Studies Summary of primary and secondary outcomes at the end of studies Key findings
Backonja et al., 2008 NPRS: Mean reduction of score is higher in treatment group (29.9%) than
control group (20.4%).
Capsaicin (NGX-4010) is safe and efficacious in reducing
pain in postherpetic neuralgia patients.
PGIC: Slightly improved, much improved and very much improved higher in
treatment group (55%) compared to control (43%).
Adverse reaction: Short lasting pain and erythema is generally mild and
moderate in treatment group.
Webster et al., 2010a NPRS: Mean reduction of score is significantly higher in treatment group
(25.0%) than control group (14.7%)
PGIC: Total improved (slightly, much and very much improved) higher in
treatment group (55%) than control group (41%).
CGIC: Total improved (slightly, much and very much improved) higher in
treatment group (52%) than control group (42%).
Adverse reaction: Mild to moderate, transient side effects are observed.
Generally well-tolerated. 1% of participants withdrawn due to side effects.
59% of treatment group patient reported adverse events. No serious
adverse events are related to treatment.
Capsaicin (NGX-4010) is efficacious in pain reduction in
postherpetic neuralgia. Lowest effective dose is required in
60-min treatment.
Webster et al., 2010b NPRS: Mean reduction of score is higher in treatment group (36.6%) than
control group (32.3%) (but no statistical significance).
PGIC: Much improved and very much improved in treatment group (43%) is
higher than control group (30%) (but no statistical significance).
CGIC: Total improved (slightly, much and very much improved) higher in
treatment group (43%) than control group (24%).
Adverse reaction: Generally well-tolerated in most participants and side
effects are manageable in most cases. 4% of participants withdrawn due to
burning and pain at application site. 75% of treatment group patient
reported adverse events. No serious adverse events related to treatment.
Although, capsaicin (NGX-4010) appeared to be safe and
well-tolerated, it failed to show significant efficacy in
participants with postherpetic neuralgia for less than
6 months.
Irving et al., 2011 NPRS: Mean reduction of score is higher in treatment group (32.3%) than
control group (25%).
PGIC: Total improved (slightly, much improved and very much improved)
higher in treatment group (61%) than control group (47%).
CGIC: Total improved (slightly, much improved and very much improved)
higher in treatment group (63%) than control group (48%).
Adverse reaction:
Higher occurrence in treatment group. Generally well-tolerated. 2% of
participants withdrawn due to side effects. There is mild to moderate skin
reactions at application site. No serious adverse events are caused by
intervention.
Capsaicin (NGX-4010) is efficacious in pain reduction for
postherpetic neuralgia.
Watson et al., 1993 Patients with PHN for more than 6 months
Visual analog pain scale: Mean reduction is slightly higher in treatment
group (20.9%) than control group (5.8%).
PGIC: Total improved higher in treatment group than control group. 65% of
treatment group versus 34% of the patients experienced reduction in PHN
pain.
CGIC: Total improved higher in treatment group than control group. 38% of
treatment group versus 20% of the patients experienced reduction in PHN
pain.
Adverse reaction:
There were no serious adverse effects observed or reported during trial.
Only burning, stinging and erythema at application sites was directly
attributable to capsaicin cream.
Patients with PHN for more than 12 months Visual analog pain
scale: Mean reduction is slightly higher in treatment group (15%) than
control group (5.2%).
PGIC: Total improved higher in treatment group than control group. 39% of
treatment group versus 6% of the patients experienced reduction in PHN
pain.
CGIC: Total improved higher in treatment group than control group. 64% of
treatment group versus 25% of the patients experienced reduction in PHN
pain.
Capsaicin cream is a safe and effective treatment for the
pain of PHN and should be considered for initial
management of patients with this condition.
(Continued)
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TABLE 3 | Continued
Studies Summary of primary and secondary outcomes at the end of studies Key findings
Adverse reaction:
There were no serious adverse effects observed or reported during trial.
Only burning, stinging and erythema at application sites was directly
attributable to capsaicin cream.
Bernstein et al., 1989 Visual analog pain scale for pain measurement: Mean reduction is
higher in treatment group (30%) than control group (1% increase).
Visual analog pain scale for pain relief: Mean reduction is higher in
treatment group (54%) than control group (6%).
PGIC: Total improved (much and very much improved) higher in treatment
group (46%) than control group (6%).
CGIC: Total improved higher in treatment group (77%) than control group
(31%).
Adverse reaction:
There are mild to moderate skin reactions at application site. No systemic
adverse events are caused by intervention.
Capsaicin could be used for initial treatment of postherpetic
neuralgia due to low systemic toxicity and no drug
interactions.
favor the treatment (capsaicin). Overall the efficacy of topical
capsaicin is moderately high. Based on Figure 5, topical capsaicin
demonstrated its highest efficacy in Webster et al. (2010a)
(highest mean reduction in NPRS score of −10.30), and its
lowest efficacy in Webster et al. (2010b) (mean reduction
in NPRS score of −4.3). It is noteworthy that the results
of Watson et al. (1993) and Webster et al. (2010b) are not
statistically significant. All six studies have acceptably low risks
of bias (as discussed previously), so the results are likely to be
valid.
It must be noted that further statistical analysis on the safety
on capsaicin could not be performed due to a lack of relevant
data. Therefore the statistical significance of the results could not
be confirmed.
DISCUSSION
Management of neuropathic pain such as PHN is more
challenging than other types of pain (Park and Moon, 2010). In
general, patients with neuropathic pain have higher pain scores
than patients with non-neuropathic pain (Park and Moon, 2010).
In addition, patients with neuropathic pain are reported to have
a lower quality-adjusted life-year (QALY) and a higher risk of
depression (Bucci et al., 1988; Park and Moon, 2010). They
also experience less pain relief with the standard treatment, so
they usually need multiple drugs and adjunctive treatments for
adequate pain management (Smith et al., 2007; Park and Moon,
2010).
For PHN patients, good adherence to medicine is particularly
important for adequate pain management. Patients need to
continuously reapply capsaicin cream throughout the day due
to the low concentration of the active ingredient (0.025–0.075%)
(Das et al., 2013). The four-times-daily application may threaten
medication compliance (Jorge et al., 2011).
While capsaicin cream (which requires frequent application)
may reduce adherence, a capsaicin patch could potentially
improve a patient’s adherence, as such a patch only needs
to be reapplied every 3 months (Das et al., 2013). This
could be accounted for by the down-regulation of TRPV-1
receptors (Jorge et al., 2011). The use of a capsaicin patch
allows the medication regimen to be simplified and hence
improves medicine adherence. The use of topical capsaicin in
place of tricyclic antidepressants and anticonvulsants (which are
commonly used to treat PHN) also eliminates the need to titrate
doses, thus minimizing the risk of side effects or withdrawal
symptoms.
Besides, topical capsaicin does not have systemic effects (e.g.,
CNS effects). As reported in one study, CNS impairment is the
least acceptable side effect of pain-relieving medicines among
chronic pain patients (Jorge et al., 2011). Hence, topical capsaicin
would be better received than other conventional treatment
options (which have significant systemic effects). The increased
patient acceptance of medicine could significantly improve
adherence and eventually lead to better pain management.
As topical capsaicin is able to provide efficient pain relief
with fewer central nervous system effects and a minimal drug
regimen burden, it seems to be an ideal candidate as a first-
line agent in the management of PHN (Bernstein et al., 1989;
Jorge et al., 2011). However, in practice, topical capsaicin is
not commonly used as first-line treatment in chronic pain
management (NICE, 2013). In fact, it is not advisable to use
topical capsaicin (capsaicin patch) for initial treatment. For
the initial treatment of PHN, the recommended first- and
second-line agents are gabapentin, a lidocaine patch, opioid
analgesics, and tricyclic antidepressants (Dworkin et al., 2003).
Like the cream formulation, capsaicin patches may cause a
burning sensation (Das et al., 2013). As placement of the patch
can be quite painful, a local topical anesthetic or opioid pain
relievers must be used concurrently during application (FDA,
2009). A capsaicin patch may also increase blood pressure
during initial application (Das et al., 2013). In fact, the FDA
recommends blood-pressure monitoring for at least an hour after
the application of a capsaicin patch. In general, the role of topical
preparations in patient adherence remains unclear, as there is a
lack of compliance studies that compare traditional routes (e.g.,
oral) and topical treatment in chronic pain management (Jorge
et al., 2011).
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TABLE 4 | Comparison of primary end point 3 and secondary endpoint: mean reduction in seven-point patient global impression of change (PGIC).
Studies Number and percentage of patients who have improved
(slightly, much and very much) at the end of the study
Number and percentage of participants
who experienced any adverse events
Treatment Control Treatment Control
Backonja et al., 2008 114 (55%) 85 (43%), 203 (99%) 174 (88%)
Webster et al., 2010a 122 (55%) 32 (41%) 131 (59%) 43 (56%)
Webster et al., 2010b 41 (43%) 15 (30%) 76 (75%) 28 (53%)
Irving et al., 2011 123 (61%) 91 (47%) 208 (98%) 177 (87%)
Watson et al., 1993 91 (64%) 17 (25%) 45 (61%) 23 (33%)
Bernstein et al., 1989 4 (46%) 1 (6%) NA NA
FIGURE 3 | Overall Risk of bias graph.
Evidence from the Included Studies
Based on the difference in mean NPRS score, most studies
have demonstrated that topical capsaicin has a moderately high
efficacy in pain reduction. This indicates that topical capsaicin
alone may adequately reduce pain. In terms of PGIC, the number
of patients who reported improvements in pain reduction is
higher in the treatment group in all seven studies. This also
suggests that topical capsaicin is able to adequately control
pain. However, the significance of these results could not be
determined. Although, the results obtained for the two primary
efficacy endpoints (NPRS and PGIC scores) correlate well with
one another (i.e., both suggest adequate pain reduction), it is
unknown whether they are equivalent in terms of accuracy and
sensitivity. Moreover, the efficacy of topical capsaicin compared
to other agents is unknown, as all the included studies only used
a placebo in the comparator arm. However, a study suggests
that topical capsaicin has significantly higher efficacy compared
to oral products (Armstrong et al., 2011). The same study also
found that the cost effectiveness of topical capsaicin is similar
or acceptable compared to other existing therapies (Armstrong
et al., 2011).
More patients in the treatment group experienced side effects
than in the control group. However, the statistical significance of
these results could not be confirmed because statistical analysis
could not be performed on the secondary outcome, due to a
lack of data. It is also unknown whether or not these side effects
are well-tolerated, as this is not described in the studies. The
severity of the side effects is also unclear. The safety profile of
topical capsaicin remains unknown and its safety could not be
established based on the limited evidence.
Potential Use of Topical Capsaicin
Based on the available evidence, it is likely that the risks of
using topical capsaicin as a first-line treatment outweigh its
benefits, due to safety concerns. In other words, the use of
topical capsaicin could possibly have an unfavorable risk-benefit
ratio. Furthermore, there is insufficient evidence on the efficacy
of topical capsaicin to support its use. Nevertheless, topical
capsaicin could be a first-line treatment option for patients who
are intolerant to oral treatment and systemic side effects, or
who have poor compliance (Das et al., 2013). Besides, it may
be suitable for patients with oral neuropathic pain. Topical
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FIGURE 4 | Summary of Risk of Bias for individual studies.
preparations can potentially benefit pediatric patients (whose
chronic pain management is no less challenging than adults),
since a significant number of the pediatric population is unable to
swallow tablets (Jorge et al., 2011; Zajicek et al., 2013). Moreover,
PHN is one of the main causes of morbidity among the elderly
(who are more resistant to treatment). Topical capsaicin could be
used for treatment of postherpetic neuralgia in the elderly due to
its low systemic toxicity and minimal drug interactions. It is also
more tolerable than other agents.
In essence, topical capsaicin could be a potential first-
line treatment of chronic pain in specific patient groups or
patients with specific conditions, for, example, elderly PHN
patients. Undeniably, the use of topical capsaicin in chronic
pain management is very limited and it is unlikely that topical
capsaicin would be widely used as a first-line treatment due to the
paucity of evidence on its efficacy and safety profile. For the time
being, it could be used as an adjunct to other conventional first-
line treatment options, as a combination treatment will usually
have a higher efficacy and tolerability (NICE, 2013).
LIMITATIONS OF EVIDENCE
It should be noted that some of the studies, including Backonja
et al. (2008) and Webster et al. (2010a,b), are funded or
sponsored. This could be a potential source of bias, as
inappropriate influence of funders is often regarded as a risk of
bias (Higgins and Green, 2011; Lexchin, 2012). There may be
potential conflicts of interest.
Blinding of outcome assessors can be especially important
for assessment of subjective outcomes, such as degree of
pain. All studies are adequately described as double-blind, but
maintenance of blinding is not well-described in some studies
(e.g., Bernstein et al., 1989). Besides, blinding may have been
broken if the participants correctly guessed which group they
were in. In that case, the participants may not be truly blinded.
Generally, blinding is considered to be broken if more than
50% of guesses are correct. To ensure adequate blinding, low-
concentration capsaicin is used in the control group instead of
an inert placebo in studies such as Webster et al. (2010a,b) and
Irving et al. (2011). However, this may confound the results of
the studies. For example, in Webster et al. (2010b), spontaneous
resolution of postherpetic neuralgia may have resulted in better
reduction of pain in the control group. Additionally, a data review
FIGURE 5 | Forest plot of treatment (capsaicin) vs. control.
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has shown that there may be a difference in pain score reporting
(PGIC) between genders. This could be a potential source of bias.
Hence, a gender-stratified analysis is required. In studies where
an NPRS score was not assessed (Bernstein et al., 1989; Watson
et al., 1993), a VAS score was instead used as a primary outcome.
CONCLUSION
Capsaicin, the main component in chili peppers, has immense
ethnopharmacological potential, and has served as one of the
main adjunctive treatments for neuropathic pain such as PHN.
The current review aimed to compile and investigate the efficacy
and safety of topical capsaicin in management of chronic pain
caused by PHN. Based on a literature search, all the six included
studies suggest that topical capsaicin is efficacious but at the
same time is associated with a higher incidence of side effects.
This prompted the need for a meta-analysis study. Based on the
analysis, five of the included studies indicated the treatment with
capsaicin has better efficacy compared to a vehicle-controlled
placebo. However, the results of two studies involving 298
out of the 1415 total pooled population are not statistically
significant. Unfortunately, the answer to the research question
remains inconclusive. Therefore, it is still unclear whether or
not topical capsaicin should be used as a first-line treatment.
Further evidence is required to determine the risk-benefit ratio
and support the use of capsaicin as a first-line treatment.
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